BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, July 18, 2026
Home » Authors » Amanda Lanier

Articles by Amanda Lanier

M&A with declining bar chart
Biopharma deals May 2023

Overall deal value keeps last year’s pace as M&A values tumble

June 9, 2023
By Amanda Lanier
Biopharma deal values are continuing to track at a similar pace to last year, down only 0.31% compared to the first five months of 2022, while there have been 173 fewer deals. M&A values are at their lowest value in all years tracked by BioWorld (2016-2023).
Read More
Dollar arrows pointing upward
Biopharma financings May 2023

Upward swing continues for biopharma financings with $25B+ raised through May

June 6, 2023
By Amanda Lanier
Biopharma financings are continuing a faster pace than last year, with $25.82 billion raised in the first five months of 2023, up 20.46% from $21.44 billion in the same time period last year. Value is down compared to 2021’s $59.29 billion and 2020’s $48.03 billion but it is more than 2019’s $23.21 billion from January to May.
Read More
Green arrow up red arrow down
Med-tech financings May 2023

Follow-on offerings up year-over-year as overall med-tech financing value continues decline

June 2, 2023
By Amanda Lanier
Med-tech companies raised $8.65 billion in the first five months of the year, a decrease of 34.9% from the $13.29 billion raised in the same time frame last year. The number of deals is down 33.04% from last year, from 230 to 154.
Read More
Dollar arrows pointing upward
Biopharma financings May 2023

Upward swing continues for biopharma financings with $25B+ raised through May

June 2, 2023
By Amanda Lanier
Biopharma financings are continuing a faster pace than last year, with $25.82 billion raised in the first five months of 2023, up 20.46% from $21.44 billion in the same time period last year. Value is down compared to 2021’s $59.29 billion and 2020’s $48.03 billion but it is more than 2019’s $23.21 billion from January to May.
Read More
FDA Approved stamp
Biopharma regulatory actions and approvals April 2023

US FDA approvals show modest growth in 2023, while global drug approvals decline

May 26, 2023
By Amanda Lanier
U.S. FDA approvals had a modest increase during the first four months of 2023 compared to last year, but still fall short of the peaks seen in 2019 and 2021.
Read More
Concept of business partnership
Biopharma deals April 2023

Fewer biopharma deals raise similar value year-over-year, while M&A value declines

May 23, 2023
By Amanda Lanier
Biopharma has experienced relatively stable deal value year-over-year, despite a 24% decline in the number of deals through April. M&As, however, have brought in the lowest amount in years.
Read More
Med-tech deals April 2023

Med-tech deals surge to highest value in years as M&As slow down

May 19, 2023
By Amanda Lanier
Med-tech has seen significant deal value growth during the first four months of 2023, despite a decline in the number of deals. In contrast, the value of mergers and acquisitions has experienced a notable downturn.
Read More
Concept of business partnership
Biopharma deals April 2023

Fewer biopharma deals raise similar value year-over-year, while M&A value declines

May 19, 2023
By Amanda Lanier
Biopharma has experienced relatively stable deal value year-over-year, despite a 24% decline in the number of deals through April. M&As, however, have brought in the lowest amount in years.
Read More
Globe and currency symbols

Despite IPO drought, biopharma financings tracking ahead of last year

May 16, 2023
By Amanda Lanier
Biopharma financings are pacing more than $300 million higher than at the end of April last year, but are well behind the total through April 2021 when the value of financings more than doubled any recent year due to the response to the COVID-19 pandemic. Through the end of April, biopharmas have raised $19.83 billion this year, compared to $17.5 billion through the same month in 2022, $53.7 billion in 2021, $24.04 billion in 2020 and $19.53 billion in 2019.
Read More
Med-tech financings April 2023

Venture capital comprises 86% of declining med-tech financings in April

May 12, 2023
By Amanda Lanier
Med-tech financings have continued to decline from 2021's peak when they brought in a combined total of $27.76 billion through April. In the first four months of 2022, that dropped 61.74% to $10.62 billion and this year they have fallen 44.16% to $5.93 billion. Broken out by type of financing, med-tech follow-ons are higher than the same period last year ($2.6 billion in early 2023 vs. $1.73 billion through April of last year).
Read More
Previous 1 2 … 42 43 44 45 46 47 48 49 50 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2026.
  • AI-generated  illustration of a neuron with tau protein aggregation

    AAIC 2026: Age of amyloid is being joined by time of tau

    BioWorld
    The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Illustration of human brain and dna

    Voyager’s gene therapy reduces tau levels in AD models

    BioWorld Science
    At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing